“Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial”, J of Skin, vol. 8, no. 6, p. s488, Nov. 2024, doi: 10.25251/skin.8.supp.488.